WEKO3
アイテム
Prognostic impact of CD168 expression in gastric cancer
http://hdl.handle.net/10232/20321
http://hdl.handle.net/10232/20321ad390e9f-9461-458a-8668-44f80f0f7494
| 名前 / ファイル | ライセンス | アクション |
|---|---|---|
Prognostic impact of CD168 expression in gastric cancer.pdf (599.4 kB)
|
|
| Item type | 学術雑誌論文 / Journal Article(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2014-01-16 | |||||
| タイトル | ||||||
| タイトル | Prognostic impact of CD168 expression in gastric cancer | |||||
| タイトル言語 | en | |||||
| 著者 |
石神, 純也
× 石神, 純也× 上野, 真一× 西園, 由香× 松本, 正隆× 蔵原, 弘× 有上, 貴明× 内門, 泰斗× 瀬戸山徹郎× 有馬, 豪男× 喜多, 芳昭× 喜島, 祐子× 北薗, 正樹× 夏越, 祥次 |
|||||
| 言語 | ||||||
| 言語 | eng | |||||
| 資源タイプ | ||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
| 資源タイプ | journal article | |||||
| 要約 | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | Background: Interactions of stromal hyaluronic acid (HA) with its binding protein RHAMM (receptor for HAmediated motility) (CD168) have been reported to affect tumor extension and the migration of crucial molecules to promote tumor progression and metastases. Cancerous CD168 expression is correlated with aggressive biological features in several cancers. However, the clinical implications of CD168 positivity in gastric cancer have remained unclear. Methods: We examined the CD168 expression of 196 consecutive gastric cancer patients by immunohistochemistry. According to CD168 positivity, the 196 gastric cancer patients were divided into two groups (57 CD168-positive and 139 CD168-negative patients). The correlation between CD168 expression and clinicopathological factors (age, sex, histology, tumor depth, lymph node status, and vessel invasion) was evaluated according to the Japanese Classification of Gastric Carcinoma. Results: Cancerous CD168 expression was detectable in 57 of the 196 tumors (29%). CD168 positivity was significantly correlated with the depth of invasion, nodal involvement, and vessel invasion (p < 0.01). Survival analysis of the 196 gastric cancer patients showed that the CD168-positive group had a significantly higher mortality than the CD168-negative group (p < 0.01). In terms of a correlation with CD168 positivity at separate clinical stages, a significance difference was only found in stages II and III. Multivariate analysis revealed that CD168 expression was a significant independent prognostic marker (p = 0.013) after depth of invasion (p < 0.005) and nodal involvement (p < 0.01). Conclusion: Our results suggest that cancerous CD168 positivity is strongly related to the invasion and metastasis of gastric cancer tumors. These results suggest that cancerous CD168 expression can be used as a prognostic marker of gastric cancer owing to its interactions with stromal hyaluronic acid. |
|||||
| 内容記述言語 | en | |||||
| 収録雑誌名 |
en : BMC Cancer 巻 11, p. 106, 発行日 2011 |
|||||
| 作成日 | ||||||
| 日付 | 2011-03-24 | |||||
| 日付タイプ | Issued | |||||
| ISSN | ||||||
| 収録物識別子タイプ | EISSN | |||||
| ISSN | 14712407 | |||||
| DOI | ||||||
| 識別子タイプ | DOI | |||||
| DOI | https://doi.org/10.1186/1471-2407-11-106 | |||||
| 権利 | ||||||
| 権利情報の言語 | en | |||||
| 権利情報 | (C) 2011 Ishigami et al; licensee BioMed Central Ltd. | |||||
| 出版タイプ | ||||||
| 出版タイプ | VoR | |||||
| 出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||
| NDC | ||||||
| 主題Scheme | NDC | |||||
| 主題 | 493 | |||||
| 公開者・出版者 | ||||||
| 出版者 | BioMed Central | |||||
| 出版者言語 | en | |||||
